

Supplemental material - Synthesis - description and raw data

All raw data are deposited in Dryad DOI <https://doi.org/10.5061/dryad.q83bk3jms>. We here describe the details of the synthesis. Reagents and solvents were obtained from commercial suppliers and used without further purification. Organic solvents were dried using molecular sieves. $^1\text{H-NMR}$ and $^{13}\text{C-NMR}$ spectra were recorded either on AV 300 MHz or on AV 600 MHz from Bruker. Chemical shifts are recorded in parts per million (ppm, δ). Spin multiplicities are described as s (singlet), d (duplet), t (triplet), q (quartet) and m (multiplet). Coupling constant (J) are recorded in Hz. NMR data were analyzed with MestReNova software. Mass analyses were performed with two different spectrometers using the same column. LCMS (method 1): Instrument: Agilent Technologies 6230 Accurate Mass TOF LC/MS linked to Agilent Technologies HPLC 1260 Series; Column: Thermo Accuore RP-MS; Particle Size: 2.6 μM Dimension: 30 x 2.1 mm; Eluent A: H_2O with 0.1 % TFA Eluent B: MeCN with 0.1 % TFA; Gradient: 0.00 min 95 % A, 0.2 min 95% A, 1.1 min 1% A, 2.5 min Stoptime, 1.3 min Posttime; Flow rate: 0.8 ml/min; UV-detection: 220 nm, 254 nm, 300 nm. LCMS (method 2): Instrument: Agilent Technologies 6120 Quadrupole LC/MS linked to Agilent Technologies HPLC 1290 Infinity; Column: Thermo Accuore RP-MS; Particle Size: 2.6 μM Dimension: 30 x 2.1 mm; Eluent A: H_2O with 0.1 % TFA Eluent B: MeCN with 0.1 % TFA; Gradient: 0.00 min 95 % A, 0.2 min 95% A, 1.1 min 1% A, 2.5 min Stoptime, 1,3 min Posttime; Flow rate: 0.8 ml/min; UV-detection: 220 nm, 254 nm, 300 nm. Purification of the compounds by chromatography was obtained using a CombiFlash Rf 200 UV-VIS System from Axel Semrau[®].




Figure 1 supporting information: 5 step synthesis of **C1-S**: a) Boc₂O, dioxane/ H_2O , quant. b) p-methoxy-aniline, HATU, HOBT, 1 eq. DIPEA, 78 %, c) TFA, DCM, quant. d) Cbz-(S)-Pro-OH, HATU, HOBT, DIPEA, 75 %, e) MeI, DMF, K_2CO_3 , 67 %.

The synthesis started with the Boc-protection of the (S)-enantiomer of 4-Hydroxyphenylglycine, followed by amidation with *para*-methoxy-aniline under standard peptide coupling conditions using 1 eq. DIPEA in order to minimize the risk of racemization to give **2** and **6** and in 78 % yield. Deprotection of the Boc-group was accomplished with TFA in DCM. The amine was coupled to (S)-Cbz-Pro-OH under standard peptide coupling conditions and subsequently purified by chromatography resulting in 75 % yield. The last step was the methylation of the Hydroxy-group using MeI in DMF under basic conditions. The same procedure was applied to the (R)-enantiomer of 4-Hydroxyphenylglycine with similar yields. In both cases no racemization of the stereocenters were observed.

(S)-2-((*tert*-Butoxycarbonyl)amino)-2-(4-hydroxyphenyl)acetic acid (**1**)

2 g (12 mmol) (S)-4-Hydroxy-phenylglycine were dissolved in dioxane/H₂O (1:1) and 3.13 g (14 mmol) of Boc₂O was added in one portion at RT. The mixture was stirred for 4 h at RT. Dioxane was removed under reduced pressure and the resulting aqueous solution was extracted EtOAc. The organic extracts were combined and dried over Na₂SO₄. After removal of the solvent 3.1 g (12 mmol) of the product was obtained as white powder in quantitative yield.

¹H NMR (300 MHz, DMSO-*d*₆) δ 7.40 (d, *J* = 8.2 Hz, 1H), 7.18 (d, *J* = 8.7 Hz, 2H), 6.71 (d, *J* = 8.6 Hz, 2H), 4.95 (d, *J* = 8.1 Hz, 1H), 1.38 (s, 9H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ 173.2, 157.5, 155.6, 129.4, 128.0, 115.5, 78.7, 60.2, 57.5, 28.7. LCMS: R_t = 1.40 min; HRMS (ESIpos): *m/z* [M+Na]⁺ calcd for C₁₃H₁₇NO₅ 290.0999 found 290.1000.

tert-Butyl-(S)-(1-(4-hydroxyphenyl)-2-((4-methoxyphenyl)amino)-2-oxoethyl)carbamate (**2**)

2.1 g (7.9 mmol) of **1** were dissolved in DMF. 986 mg (7.9 mmol) *p*-anisidine, 1.2 g (7.9 mmol) HOBt, 2.99 g (7.9 mmol) HATU and 1.37 ml (7.9 mmol, 1 eq) DIPEA were added at RT. The mixture was stirred for 4 h at RT. DMF was evaporated and the mixture was dissolved in EtOAc. The organic solution was extracted with 1N HCl solution to remove DIPEA and HOBt. The organic layer was dried over Na₂SO₄ and the crude product was purified by chromatography on silica gel eluting with a gradient of DCM/MeOH. The fractions containing the product were combined and the solvent evaporated under reduced pressure. Yield: 2.3 g (78%).

¹H NMR (300 MHz, DMSO-*d*₆) δ 10.00 (s, 1H), 9.43 (s, 1H), 7.48 (d, *J* = 9.1 Hz, 2H), 7.27 (d, *J* = 8.6 Hz, 2H), 6.87 (d, *J* = 9.2 Hz, 2H), 6.72 (d, *J* = 8.6 Hz, 2H), 5.19 (d, *J* = 8.2 Hz, 1H), 3.70 (s, 3H), 1.39 (s, 9H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ 169.5, 157.4, 155.7, 155.5, 132.5, 129.0, 121.0, 115.5, 114.3, 78.7, 58.3, 55.6, 28.7. LCMS: R_t = 1.67 min; HRMS (ESIpos): *m/z* [M+H]⁺ calcd for C₁₃H₁₇NO₅ 373.1758 found 373.1555.

(S)-2-Amino-2-(4-hydroxyphenyl)-N-(4-methoxyphenyl)acetamide (**3**)

2.3 g (6.1 mmol) of **2** were dissolved in 100 ml DCM/TFA mixture (9:1) and stirred at RT for 1 h. The solvent was removed under reduced pressure and EE/hexane was added several times and iteratively removed under reduced pressure until a white foam was contained. Yield: 2.6 g (quant.)

¹H NMR (300 MHz, DMSO-*d*₆) δ 10.46 (s, 1H), 8.63 (s, 2H), 7.49 (d, *J* = 9.2 Hz, 2H), 7.37 (d, *J* = 8.8 Hz, 2H), 6.91 (d, *J* = 9.2 Hz, 2H), 6.83 (d, *J* = 8.7 Hz, 2H), 4.96 (s, 1H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ 166.3, 158.8, 156.2, 131.6, 129.8, 124.3, 121.3, 116.0, 114.5, 56.2, 55.6. LCMS: R_t = 0.58 min; HRMS (ESIpos): *m/z* [M+H]⁺ calcd for C₁₅H₁₆N₂O₃ 273.1234 found 273.1234.

Benzyl-(S)-2-(((S)-1-(4-hydroxyphenyl)-2-((4-methoxyphenyl)amino)-2-oxoethyl)-carbamoyl)-pyrrolidine-1-carboxylate (**4**)

2.6 g (6.7 mmol) of **3** were dissolved in 60 ml DMF and 1.68 g (6.7 mmol) Cbz-(S)-Pro-OH, 1.0 g (6.7 mmol) HOBt, 2.56 g (6.7 mmol) HATU and 2.3 ml (13.5 mmol) DIPEA were added. The mixture was stirred for 1h and the solvent was removed under reduced pressure. The mixture was dissolved in EtOAc and extracted with 1N HCl. The organic layer was dried with Na₂SO₄ and removed under reduced pressure. The crude product was purified by chromatography on silica gel eluting with a gradient of DCM/MeOH. The fractions containing the product were combined and the solvent evaporated under reduced pressure. Yield: 2.55 g (75%).

¹H-NMR (300 MHz, DMSO-*d*₆) δ cis/trans (10.11 (s, 1H) and 10.05 (s, 1H)), cis/trans (9.48 (s, 1H) and 9.45 (s, 1H)), cis/trans (8.57 (d, *J* = 7.4 Hz, 1H) and 8.50 (d, *J* = 7.3 Hz, 1H)), 7.49 (d, *J* = 8.5 Hz, 2H), 7.41 - 7.33 (m, 2H), 7.32 - 7.18 (m, 5H), 6.87 (d, *J* = 8.5 Hz, 2H), 6.79 - 6.66 (m, 2H), cis/trans (5.45 (d, *J* = 7.3 Hz, 1H) and 5.41 (d, *J* = 7.4 Hz, 1H)), cis/trans (5.07 (s, 2H) and 5.00 - 4.89 (m, 2H)), cis/trans (4.47 (dd, *J* = 8.7, 3.5 Hz, 1H) and 4.40 (dd, *J* = 8.7, 3.1 Hz, 1H)), 3.71 (s, 3H), 3.50 - 3.38 (m, 2H), 2.22 - 2.05 (m, 1H), 1.95 - 1.73 (m, 3H). ¹³C-NMR (75 MHz, DMSO-*d*₆): cis/trans (172.4 and 172.0), 169.1, 157.5, 155.7, cis/trans (137.5 and 137.4), 132.5, 129.1, 129.0, 128.9, cis/trans (128.6 and 128.5), 128.2, 127.9, 127.4, 120.9, 115.6, 114.3, cis/trans (66.3 and 66.2), cis/trans (59.8 and 59.1), cis/trans (57.0 and 56.9), 55.6, cis/trans (47.6 and 47.0), cis/trans (31.7 and 30.5), cis/trans (24.4 and 23.5). LCMS: R_t = 1.71 min; HRMS (ESIpos): *m/z* [M+Na]⁺ calcd for C₂₈H₂₉N₃O₆ 526.1942 found 526.1949.

Benzyl-(S)-2-(((S)-(4-methoxyphenylcarbamoyl)(4-methoxyphenyl)methylcarbamoyl)pyrrolidine-1-carboxylate (**C1-S**).

200 mg (0.4 mmol) of **4** were dissolved in 4 ml DMF. 110 mg K₂CO₃ (0.8 mmol) and 25 μl (0.4 mmol) MeI were added. The mixture was stirred for 16 h at RT. K₂CO₃ was filtered off, the solvent and MeI were removed under reduced pressure and the crude product was purified by chromatography on silica gel eluting with a gradient of Hex/EE. The fractions containing the product were combined and the solvent evaporated under reduced pressure. Yield: 140 mg (67%).

$^1\text{H-NMR}$ (300 MHz, $\text{DMSO-}d_6$) δ cis/trans (10.11 (s, 1H) and 10.05 (s, 1H)), cis/trans (8.58 (d, $J = 7.3$ Hz, 1H) and 7.49 (d, $J = 9.1$ Hz, 1H)), 7.49 (d, $J = 8.9$ Hz, 2H), 7.45 - 7.31 (m, 4H), 7.28 - 7.21 (m, 3H), 6.94 (d, $J = 8.9$ Hz, 1H), 6.90 - 6.83 (m, 3H), cis/trans (5.52 (d, $J = 7.6$ Hz, 1H) and 5.48 (d, $J = 7.6$ Hz, 1H)), cis/trans (5.07 (s, 2H) and 5.00 - 4.89 (m, 2H)), cis/trans (4.49 (dd, $J = 8.5, 3.5$ Hz, 1H) and 4.41 (dd, $J = 8.6, 3.1$ Hz, 1H)), 3.71 (s, 6H), 3.349 - 3.36 (m, 2H), 2.27 - 2.04 (m, 1H), 1.94 - 1.73 (m, 3H). $^{13}\text{C NMR}$ (75 MHz, $\text{DMSO-}d_6$) δ cis/trans (172.4 and 172.1), cis/trans (168.9 and 168.9), cis/trans (159.3 and 159.3), 155.7, cis/trans (154.5 and 154.2), cis/trans (137.5 and 137.4), 132.4, cis/trans (130.4 and 130.3), 129.0, 128.9, 128.6, 128.2, 127.9, 127.3, 121.0, 114.3, 114.3, 114.2, cis/trans (66.3 and 66.1), cis/trans (59.8 and 59.2), 56.8, 56.7, cis/trans (55.6 and 55.6), cis/trans (47.6 and 47.0), cis/trans (31.8 and 30.5), cis/trans (24.4 and 23.5). LCMS: $R_t = 1.91$ min; HRMS (ESIpos): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{31}\text{N}_3\text{O}_6$ 518.2286 found 518.2288.

The same procedures were applied to synthesize the **C1-R**.

(R)-2-((*tert*-Butoxycarbonyl)amino)-2-(4-hydroxyphenyl)acetic acid (**5**)

LCMS: $R_t = 0.98$ min; MS (ESIpos) $m/z = 290.1$ $[\text{M}+\text{Na}]^+$.

tert-Butyl-(R)-1-(4-hydroxyphenyl)-2-((4-methoxyphenyl)amino)-2-oxoethyl)carbamate (**6**)

$^1\text{H NMR}$ (300 MHz, $\text{DMSO-}d_6$) δ 10.00 (s, 1H), 9.43 (s, 1H), 7.48 (d, $J = 9.1$ Hz, 2H), 7.27 (d, $J = 8.7$ Hz, 2H), 6.87 (d, $J = 9.2$ Hz, 2H), 6.72 (d, $J = 8.6$ Hz, 2H), 5.18 (d, $J = 8.2$ Hz, 1H), 3.70 (s, 3H), 1.39 (s, 9H). $^{13}\text{C NMR}$ (75 MHz, $\text{DMSO-}d_6$) δ 169.5, 157.4, 155.7, 155.5, 132.5, 129.2, 129.0, 121.0, 115.5, 114.3, 78.7, 58.3, 55.6, 28.6. LCMS: $R_t = 1.16$ min; MS (ESIpos) $m/z = 395.5$ $[\text{M}+\text{Na}]^+$.

(R)-2-Amino-2-(4-hydroxyphenyl)-N-(4-methoxyphenyl)acetamide (**7**)

$^1\text{H NMR}$ (300 MHz, $\text{DMSO-}d_6$) δ 10.45 (s, 1H), 8.62 (s, 2H), 7.49 (d, $J = 9.2$ Hz, 2H), 7.37 (d, $J = 8.8$ Hz, 2H), 6.91 (d, $J = 9.2$ Hz, 2H), 6.83 (d, $J = 8.7$ Hz, 2H), 4.95 (s, 1H), 3.72 (s, 3H). $^{13}\text{C NMR}$ (75 MHz, $\text{DMSO-}d_6$) δ 166.3, 158.8, 156.2, 131.6, 129.8, 124.3, 121.3, 116.0, 114.5, 56.2, 55.6. LCMS: $R_t = 0.84$ min; MS (ESIpos) $m/z = 273.1$ $[\text{M}+\text{H}]^+$.

Benzyl-(S)-2-(((R)-1-(4-hydroxyphenyl)-2-((4-methoxyphenyl)amino)-2-oxoethyl)carbamoyl)-pyrrolidine-1-carboxylate (**8**)


$^1\text{H NMR}$ (300 MHz, $\text{DMSO-}d_6$) δ cis/trans (10.22 (s, 1H) and 10.02 (s, 1H)), 9.45 (s, 1H), 8.73 - 8.65 (m, 1H), 7.57 - 7.48 (m, 2H), 7.40 - 7.32 (m, 2H), 7.30 - 7.08 (m, 5H), 6.89 (d, $J = 9.2$ Hz, 2H), 6.74 (d, $J = 7.9$ Hz, 2H), cis/trans (5.59 (d, $J = 8.2$ Hz, 1H) and 5.49 (d, $J = 7.9$ Hz, 1H)), cis/trans (5.08 (s, 2H) and

4.99 (s, 2H)), cis/trans (4.48 (dd, dd, $J = 8.2, 3.8$ Hz 1H) and 4.40 (dd, $J = 8.2, 3.9$ Hz, 1H)), 3.47 - 3.38 (m, 2H), 2.22 - 2.04 (m, 1H), 1.87 - 1.68 (m, 3H). ^{13}C NMR (75 MHz, $\text{DMSO-}d_6$) δ cis/trans (172.0 and 171.9), 168.8, 157.4, cis/trans (155.8 and 155.8), cis/trans (154.6 and 154.2), cis/trans (137.4 and 137.3), cis/trans (132.5 and 132.3), 129.5, 129.4, 128.9, 128.6, 128.4, 128.2, 127.9, 127.7, 127.4, cis/trans (121.2 and 121.0), 115.6, 114.3, cis/trans (66.4 and 66.3), cis/trans (60.2 and 60.0), cis/trans (56.6 and 56.3), 55.6, cis/trans (47.6 and 47.1), cis/trans (31.7 and 30.4), cis/trans (24.4 and 23.5). LCMS: $R_t = 1.72$ min; HRMS (ESIpos): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{28}\text{H}_{29}\text{N}_3\text{O}_6$ 504.1929 found 504.1942.

Benzyl-(S)-2-(((R)-1-(4-methoxyphenyl)-2-((4-methoxyphenyl)amino)-2-oxoethyl)carbamoyl)-pyrrolidine-1-carboxylate (**C1-R**)

^1H NMR (300 MHz, $\text{DMSO-}d_6$) δ cis/trans (10.26 (s, 1H) and 10.08 (s, 1H)), cis/trans (8.78 (d, $J = 8.4$ Hz, 1H) and 8.75 (d, $J = 7.9$ Hz, 1H)), 7.56 - 7.47 (m, 2H), 7.42 - 7.34 (m, 4H), 7.31 - 7.08 (m, 3H), 6.95 - 6.86 (m, 4H), cis/trans (5.65 (d, $J = 8.3$ Hz, 1H) and 5.56 (d, $J = 8.1$ Hz, 1H)), cis/trans (5.09 (s, 2H) and 5.00 (s, 2H)), cis/trans (4.49 (dd, $J = 8.6, 3.5$ Hz, 1H) and 4.41 (dd, $J = 8.6, 3.8$ Hz, 1H)), 3.49 - 3.38 (m, 2H), 2.22 - 2.06 (m, 1H), 1.87 - 1.68 (m, 3H). ^{13}C NMR (75 MHz, $\text{DMSO-}d_6$) δ ^{13}C NMR (75 MHz, $\text{DMSO-}d_6$) δ cis/trans (172.1 and 171.9), 168.6, 159.2, cis/trans (155.9 and 155.8), cis/trans (154.6 and 154.2), cis/trans (137.4 and 137.3), cis/trans (132.4 and 132.2), cis/trans (131.3 and 131.2), 128.9, 128.6, 128.4, 128.2, 127.9, 127.7, 127.4, cis/trans (121.2 and 121.0), cis/trans (114.4 and 114.3), cis/trans (66.4 and 66.3), cis/trans (60.0 and 59.4), cis/trans (56.5 and 56.2), 55.6, 55.6, cis/trans (47.6 and 47.1), cis/trans (31.7 and 30.5), cis/trans (24.4 and 23.5). LCMS: $R_t = 1.86$ min; HRMS (ESIpos): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{31}\text{N}_3\text{O}_6$ 518.2286 found 518.2288.

KM-06-179-170426.10.fid
KM-06-179, DMSO





KM-06-179-170426.11.fid
KM-06-179, DMSO

172.44
172.06
168.90
168.86
159.33
159.27
155.74
154.51
154.20
137.49
137.40
132.44
130.45
130.35
129.02
128.86
128.62
128.21
127.87
127.28
120.96
114.35
114.28
114.22



66.27
66.15
59.82
59.16
56.82
56.72
55.61
55.58
47.64
47.03

31.76
30.52
24.39
23.55

^{13}C NMR (75 MHz, DMSO) δ 172.44, 172.06, 168.90, 168.86, 159.33, 159.27, 155.74, 154.51, 154.20, 137.49, 137.40, 132.44, 130.45, 130.35, 129.02, 128.86, 128.62, 128.21, 127.87, 127.28, 120.96, 114.35, 114.28, 114.22, 66.27, 66.15, 59.82, 59.16, 56.82, 56.72, 55.61, 55.58, 47.64, 47.03, 31.76, 30.52, 24.39, 23.55.



Qualitative Compound Report




User Chromatogram Peak List

| Compound Name | Compound Number | RT | Height | Height % | Area | Area % | Area Sum % | Width |
|---------------|-----------------|-------|---------|----------|---------|--------|------------|-------|
| Cpd 1: 1.937 | 1 | 1.911 | 3500.33 | 100 | 9275.18 | 100 | 100 | 0.222 |

Compound Table



| Compound Label | RT | Mass | Abund | Formula | Tgt Mass | Diff (ppm) | Purity Value | Purity Result |
|----------------------|-------|----------|--------|---------------|----------|------------|--------------|---------------|
| Cpd 1: C29 H31 N3 O6 | 1.937 | 517.2219 | 540398 | C29 H31 N3 O6 | 517.2213 | 1.12 | 100 | Pass |

| Compound Label | m/z | RT | Algorithm | Mass |
|----------------------|----------|-------|-----------------|----------|
| Cpd 1: C29 H31 N3 O6 | 518.2286 | 1.937 | Find By Formula | 517.2219 |



MS Spectrum


Qualitative Compound Report



Chemical Formula: C₂₉H₃₁N₃O₆
 Exact Mass: 517,2213
 Molecular Weight: 517,5820

| | |
|--|--|
| | |
|--|--|

KM-06-170-170322.10.fid
KM-06-170, DMSO





KM-06-170-170322.11.fid
KM-06-170, DMSO

172.09
171.88
168.61
159.20
155.81
154.59
154.24
137.43
137.28
132.39
132.21
131.33
131.16
128.86
128.63
128.40
128.24
127.91
127.75
127.36
121.22
121.01
114.36
114.30

66.27
60.00
59.41
56.52
56.18
55.62
55.56
47.62
47.08

31.73
30.45
24.43
23.55



^{13}C NMR (75 MHz, DMSO) δ (172.09, 171.88, rotamers) 168.61, 159.20, 155.81, (154.59, 154.24, rotamers), (137.43, 137.28, rotamers), (132.39, 132.21, rotamers), (131.33, 131.16, rotamers), 128.86, 128.63, (128.40, 128.24, rotamers), (127.91, 127.75, rotamers), 127.36, (121.22, 121.01, rotamers) (114.36, 114.30, rotamers), 66.27, (60.00, 59.41, rotamers), (56.52, 56.18, rotamers), (55.62, 55.56, rotamers) (47.62, 47.08, rotamers), (31.73, 30.45, rotamers), (24.43, 23.55, rotamers).



Qualitative Analysis Report

User Chromatograms


Fragmentor Voltage 150 Collision Energy 0 Ionization Mode ESI



Integration Peak List

| Peak | Start | RT | End | Height | Area | Area % |
|------|-------|-------|-------|---------|--------|--------|
| 1 | 1.808 | 1.861 | 2.029 | 3362.88 | 6440.1 | 100 |



Compounds



Qualitative Analysis Report

User Spectra

Fragmentor Voltage 150 Collision Energy 0 Ionization Mode ESI



Chemical Formula: C₂₉H₃₁N₃O₆
 Exact Mass: 517,2213
 Molecular Weight: 517,5820

